203 related articles for article (PubMed ID: 16818370)
1. TLR9 in health and disease.
Vollmer J
Int Rev Immunol; 2006; 25(3-4):155-81. PubMed ID: 16818370
[TBL] [Abstract][Full Text] [Related]
2. CpG motifs to modulate innate and adaptive immune responses.
Vollmer J
Int Rev Immunol; 2006; 25(3-4):125-34. PubMed ID: 16818368
[TBL] [Abstract][Full Text] [Related]
3. TLR9 and the recognition of self and non-self nucleic acids.
Lamphier MS; Sirois CM; Verma A; Golenbock DT; Latz E
Ann N Y Acad Sci; 2006 Oct; 1082():31-43. PubMed ID: 17145922
[TBL] [Abstract][Full Text] [Related]
4. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.
Krieg AM; Vollmer J
Immunol Rev; 2007 Dec; 220():251-69. PubMed ID: 17979852
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
7. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance.
Berghöfer B; Frommer T; König IR; Ziegler A; Chakraborty T; Bein G; Hackstein H
Clin Exp Allergy; 2005 Sep; 35(9):1147-54. PubMed ID: 16164440
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
9. Innate immune recognition of, and regulation by, DNA.
Ishii KJ; Akira S
Trends Immunol; 2006 Nov; 27(11):525-32. PubMed ID: 16979939
[TBL] [Abstract][Full Text] [Related]
10. TLR9 as a key receptor for the recognition of DNA.
Kumagai Y; Takeuchi O; Akira S
Adv Drug Deliv Rev; 2008 Apr; 60(7):795-804. PubMed ID: 18262306
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning and characterization of equine Toll-like receptor 9.
Zhang YW; Davis EG; Blecha F; Wilkerson MJ
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):209-19. PubMed ID: 18462806
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
Merrell MA; Ilvesaro JM; Lehtonen N; Sorsa T; Gehrs B; Rosenthal E; Chen D; Shackley B; Harris KW; Selander KS
Mol Cancer Res; 2006 Jul; 4(7):437-47. PubMed ID: 16849519
[TBL] [Abstract][Full Text] [Related]
13. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.
Nakano S; Morimoto S; Suzuki J; Nozawa K; Amano H; Tokano Y; Takasaki Y
Rheumatology (Oxford); 2008 Feb; 47(2):145-9. PubMed ID: 18160420
[TBL] [Abstract][Full Text] [Related]
14. TLR9-mediated recognition of DNA.
Müller T; Hamm S; Bauer S
Handb Exp Pharmacol; 2008; (183):51-70. PubMed ID: 18071654
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of TLR9 activation.
Latz E; Visintin A; Espevik T; Golenbock DT
J Endotoxin Res; 2004; 10(6):406-12. PubMed ID: 15588423
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-alpha.
Schroeder JT; Chichester KL; Bieneman AP
J Allergy Clin Immunol; 2008 Feb; 121(2):486-91. PubMed ID: 18036648
[TBL] [Abstract][Full Text] [Related]
17. Regulatory molecules required for nucleotide-sensing Toll-like receptors.
Saitoh S; Miyake K
Immunol Rev; 2009 Jan; 227(1):32-43. PubMed ID: 19120473
[TBL] [Abstract][Full Text] [Related]
18. Cathepsins are required for Toll-like receptor 9 responses.
Matsumoto F; Saitoh S; Fukui R; Kobayashi T; Tanimura N; Konno K; Kusumoto Y; Akashi-Takamura S; Miyake K
Biochem Biophys Res Commun; 2008 Mar; 367(3):693-9. PubMed ID: 18166152
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells.
Marshak-Rothstein A; Busconi L; Lau CM; Tabor AS; Leadbetter EA; Akira S; Krieg AM; Lipford GB; Viglianti GA; Rifkin IR
J Endotoxin Res; 2004; 10(4):247-51. PubMed ID: 15373969
[TBL] [Abstract][Full Text] [Related]
20. Baseless assumptions: activation of TLR9 by DNA.
Gangloff M; Gay NJ
Immunity; 2008 Mar; 28(3):293-4. PubMed ID: 18342000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
